🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

RPG Life Sciences Limited RPGLIFE NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.rpglifesciences.com
Company Profile ↓
₹2,721.60
+19.91% 1Y
Mkt Cap₹4,501.26 Cr
P/E39.08
P/B7.27
Div. Yield0.89%
52W High₹3,017.10
52W Low₹1,726.93
Book Value₹366.01
EPS (TTM)₹69.64

Company Overview

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 24.5%.

Consistent Profit Growth

Net profit has compounded at 19.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.3% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 39.1, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 16.4%.

Recent Developments

  • Mar 2026 Revenue of ₹702.00 Cr (+8.4% YoY); net profit ₹115.17 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +8.4%, earnings -37.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.3%, profit CAGR 19.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.31%
1 Year:8.41%

Compounded Profit Growth

5 Years:19.41%
1 Year:-37.15%

Stock Price Performance

1 Year:+19.91%
6 Months:+46.80%
3 Months:+29.82%
1 Month:+1.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 77% of range
₹1,726.93 ₹3,017.10
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.77 · Neutral
Price Performance
1M+1.22%
3M+29.82%
6M+46.80%
1Y+19.91%
Valuation vs Sector

P/E of 39.08 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 24.5%.
  • Compounding revenue at 11.3% over 5 years.
  • Profit CAGR of 19.4% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
39.08
Industry PE
41.64
Forward P/E
95.23
PEG Ratio
-
Book Value
₹366.01
Price to Book
7.27
P/S
5.99
EV/EBITDA
26.94
Dividend Yield
0.89%

Growth (CAGR)

Revenue 5Y
11.31%
Profit 5Y
19.41%
Revenue (YoY)
8.41%
Earnings (YoY)
-37.15%

Profitability & Returns

ROCE
24.52%
ROE
19.03%
ROA
14.52%
Profit Margin
16.41%
Op Margin
18.05%
Gross Margin
62.70%
EPS (Latest Qtr)
₹18.60
EPS (TTM)
₹69.64

Balance Sheet & Liquidity

Debt/Equity
3.30
Quick Ratio
2.71
Current Ratio
3.48
Debt
₹20.00 Cr
Total Assets
₹793.16 Cr
Current Assets
₹559.48 Cr
Working Capital
₹398.91 Cr

Ownership

Promoter Holding
76.45%
Chg in Prom Hold
1.15%
FII / Inst Holding
5.55%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹4,501.26 Cr
Total Revenue (TTM)
₹702.00 Cr
EBITDA
₹176.57 Cr
Free Cash Flow
₹-8.86 Cr
Operating Cash Flow
₹56.50 Cr
Shares Outstanding
₹1.65 Cr
Gross Margin
62.70%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RPGLIFE RPG Life Sciences Limited NSEPHARMA 2,721.60 39.08 ₹4,501.26 Cr 0.89% 24.52% 19.03% 11.31% 19.41%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -172.71 Cr143.09 Cr168.92 Cr182.00 Cr180.03 Cr176.89 Cr195.69 Cr
Cost of Revenue -56.11 Cr48.72 Cr60.02 Cr-64.90 Cr60.59 Cr68.15 Cr
Gross Profit -116.60 Cr94.37 Cr108.90 Cr-115.13 Cr116.30 Cr127.54 Cr
Operating Expenses -72.90 Cr74.25 Cr78.57 Cr143.00 Cr80.75 Cr89.21 Cr90.15 Cr
Operating Income -43.70 Cr20.12 Cr30.33 Cr34.00 Cr34.38 Cr27.09 Cr37.39 Cr
EBITDA -52.47 Cr140.45 Cr40.70 Cr39.00 Cr34.75 Cr46.33 Cr47.99 Cr
Interest Expense -12.00 L18.00 L13.00 L025.00 L39.00 L63.00 L
Pretax Income -46.89 Cr134.90 Cr35.43 Cr49.00 Cr29.12 Cr40.20 Cr41.46 Cr
Tax Provision -11.96 Cr17.55 Cr9.14 Cr12.25 Cr6.99 Cr10.30 Cr10.70 Cr
Net Income -34.93 Cr117.35 Cr26.29 Cr37.00 Cr22.13 Cr29.90 Cr30.76 Cr
Diluted EPS -21.1270.9615.9022.2813.3818.0818.60

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -509.08 Cr577.48 Cr647.54 Cr702.00 Cr
Cost of Revenue -178.23 Cr194.20 Cr223.92 Cr261.85 Cr
Gross Profit -330.85 Cr383.28 Cr423.62 Cr440.15 Cr
Operating Expenses -241.97 Cr271.21 Cr283.25 Cr313.46 Cr
Operating Income -88.88 Cr112.07 Cr140.37 Cr126.69 Cr
EBITDA -107.49 Cr135.36 Cr254.93 Cr176.57 Cr
Interest Expense -31.00 L45.00 L62.00 L89.00 L
Pretax Income -91.68 Cr117.84 Cr232.88 Cr154.20 Cr
Tax Provision -24.04 Cr30.18 Cr49.64 Cr39.03 Cr
Net Income -67.64 Cr87.66 Cr183.24 Cr115.17 Cr
Diluted EPS -40.9053.01110.8069.64

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -419.35 Cr512.87 Cr657.81 Cr793.16 Cr
Current Assets -264.05 Cr298.09 Cr465.25 Cr559.48 Cr
Cash & Equivalents -24.82 Cr19.72 Cr28.70 Cr150.46 Cr
Inventory -95.05 Cr101.00 Cr92.98 Cr123.84 Cr
Receivables -37.43 Cr49.13 Cr86.76 Cr116.68 Cr
Total Liabilities -111.75 Cr138.02 Cr127.28 Cr187.81 Cr
Current Liabilities -102.78 Cr130.96 Cr119.83 Cr160.57 Cr
Long Term Debt 1.00 L0--13.33 Cr
Total Debt 94.00 L1.00 L0-20.00 Cr
Total Equity -307.60 Cr374.85 Cr530.53 Cr605.35 Cr
Shares Outstanding -1.65 Cr1.65 Cr1.65 Cr1.65 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -90.82 Cr94.36 Cr77.86 Cr56.50 Cr
Investing Cash Flow --105.81 Cr-79.15 Cr-41.80 Cr85.84 Cr
Financing Cash Flow --17.12 Cr-20.31 Cr-27.08 Cr-20.58 Cr
Capital Expenditure --32.73 Cr-69.23 Cr-36.03 Cr-65.36 Cr
Free Cash Flow -58.09 Cr25.13 Cr41.83 Cr-8.86 Cr
Net Change in Cash --32.11 Cr-5.10 Cr8.98 Cr121.76 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -65.0%66.4%65.4%62.7%
Operating Margin % -17.5%19.4%21.7%18.0%
Net Margin % -13.3%15.2%28.3%16.4%
ROE % -22.0%23.4%34.5%19.0%
ROCE % -28.1%29.3%26.1%20.0%

Shareholding Pattern

Insiders
76.45%
Institutions
5.55%
Public Float
23.59%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RPGLIFE

Google News Mon, 07 Sep 2026

RPG Life Sciences To Deploy Rs 500 Cr in Next 12 Months To Bolster Manufacturing, API Capabilities - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOTDJ3RkZLV2N4em50akpGZEtDbzVDeV9pcTkyZ0ROUE1xM3ktZVdBMmR4blVnR25fcjdoeVFZSG9XS05Yc0NNX1BYdEF6RUNaX1k4N1RRbzR2c1Q4WWVnMFMybTZyaTNrZkFUbFpiV0lWaTg3SnJxVEVsS3VBcHVPVFFGUVl1cnM1M0NEQm…

Google News hu, 07 May 2026

Why RPG Life Sciences' (NSE:RPGLIFE) Shaky Earnings Are Just The Beginning Of Its Problems - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOLXRUcWk3WG12TzllbmUxbU5FSVJJbi1yNm1UR0JLQ1Vta3pmSjJyWkJQM2RpYlRmTzg5Smc4eV84d1h5ZlNXQzFvcVBBbHRhN1hsaU1Jd0dodkxmVUVsWEs2M0tiV0xXSmRHR1VhSFJTaWRsdzN6THI3d012UUVXd3dZWmdHM2ROSGFRYz…

Google News Wed, 02 Sep 2026

RPG Life Sciences posts Sep 3 investor call details on website - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNYjZzNUd3TTNNbnFIRGdGRC1BS3lZd1JQUEk3cElBamRfbmZpWHRESFpZX3J3bTJ4c0toaEt0WlVqYmtwTWcyZHVTekhsX1VHRmlhSXhKbmktN2dNSGdmNXBQMHFfQU9FWTZGRnZBXzJLYXFxN1ZfcWM5ekdtLWVURzdiWHl0bS1IWTJxSU…

Google News hu, 03 Sep 2026

RPG Life Sciences Subsidiary Acquires Raghava Life Sciences’ API Biz for Rs 135 Cr - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRVNGTmxZRGM2OVZiTmpCbFZ5cDJ6REJma081NGl1ckc3elBMOGc4SW9qNUhWdzBwV2JwN0ZwcFljeXRJS3VBNExua29HcW5OS0ZZallSU0g1ckowMDNPMm1adDR5QlBqckVtRGVEcXBwNGtfUUxwSW9qbGJOS0M0dWxLSGhUaDBtTjBCdT…

Google News Mon, 22 Jun 2026

RPG Life Sciences (RPGLIFE.NS) Edges Higher: Stock Trades Near Resistance at ₹2,429 - Moving Average Ribbon - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOZUYwbVpJMmFZY0ZCeTNhRkR5dHdhQVlRakkwU2F6bm40UVdZUVpwRURrUXF1WGp2MWlRcmphalY1UVlvSXFkMXhVWGZpanlFQ0FyU0ptX2VyelhBaUFOMlR5M2diblpaVk82OW83YWtiai1jMlRSRE11bXdDYUtMLWtMQ3FEdTJId2lqRX…

Google News hu, 30 Apr 2026

Q4 earnings, dividend news trigger 14% jump in RPG Life Sciences shares - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNcXVXR2QwdUhBaEdya0ZBWXE0NzhVMjJPX3ZGUU9xTEZOR0lZTDZfbTJsbC1hcDQ5MV94b05ON2lOa0V5bVVSel93YjVGOFFQY1NXTnBiU1VGM2wxekxtRERGeHpYQTJ5OE5VaWpSeGpNM1FIRjQ2Q3AwOVZNMWxIRWRWWWVNRGNydlVOb0…

RPGLIFE — Frequently Asked Questions

What is the current share price of RPG Life Sciences Limited (RPGLIFE)?

As of 2026-09-08 04:53 IST, RPG Life Sciences Limited (RPGLIFE) trades at ₹2,721.60 on NSE. Its 52-week range is ₹1,726.93 to ₹3,017.10.

What is the market capitalisation of RPGLIFE?

RPG Life Sciences Limited (RPGLIFE) has a market capitalisation of ₹4,501.26 Cr on NSE.

What is the P/E ratio of RPGLIFE?

RPGLIFE trades at a trailing price-to-earnings (P/E) ratio of 39.08. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 7.27.

Does RPGLIFE pay a dividend?

RPG Life Sciences Limited (RPGLIFE) currently offers a dividend yield of 0.89%.

What is the return on equity (ROE) of RPGLIFE?

RPGLIFE has a return on equity (ROE) of 19.03%. Its return on capital employed (ROCE) is 24.52%.

Is RPGLIFE a good stock to buy?

This page provides a data-driven analysis of RPG Life Sciences Limited (RPGLIFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space